Placebo + ARD-101
Phase 3Active 0 views this week 0 watching💤 Quiet
Interest: 34/100
34
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Hyperphagia
Conditions
Hyperphagia, Prader-Willi Syndrome
Trial Timeline
Dec 20, 2024 → Apr 1, 2026
NCT ID
NCT06828861About Placebo + ARD-101
Placebo + ARD-101 is a phase 3 stage product being developed by Aardvark Therapeutics for Hyperphagia. The current trial status is active. This product is registered under clinical trial identifier NCT06828861. Target conditions include Hyperphagia, Prader-Willi Syndrome.
What happened to similar drugs?
0 of 3 similar drugs in Hyperphagia were approved
Approved (0) Terminated (0) Active (3)
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06828861 | Phase 3 | Active |
Competing Products
3 competing products in Hyperphagia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Carbetocin | Acadia Pharmaceuticals | Phase 3 | 44 |
| Carbetocin + Placebo | Acadia Pharmaceuticals | Phase 3 | 41 |
| ARD-101 | Aardvark Therapeutics | Phase 3 | 34 |